OverviewSuggest Edit

Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. The company’s aim is a commercial-stage biopharmaceutical company in the area of immunotherapy and focuses on the research in medical needs in cancer.

TypePublic
Founded1999
HQMarseille, FR
Websiteinnate-pharma.com

Latest Updates

Employees (est.) (Dec 2019)235(+13%)
Revenue (FY, 2019)€85.8 M(-8%)
Share Price (Aug 2020)€5.2
Cybersecurity ratingBMore

Key People/Management at Innate Pharma

Herve Brailly

Herve Brailly

Co-founder & Chairman of the Supervisory Board
Odile Laurent

Odile Laurent

Vice President, Human Resources Director
Irina Staatz-Granzer

Irina Staatz-Granzer

Vice-Chairman
Mondher Mahjoubi

Mondher Mahjoubi

Chairman of the Executive Board and Chief Executive Officer
Maïlys Ferrere

Maïlys Ferrere

Board Member
Laure-Hélène Mercier

Laure-Hélène Mercier

Executive Vice President, Chief Financial Officer and Member of the Executive Board
Show more

Innate Pharma Office Locations

Innate Pharma has offices in Marseille and Rockville
Marseille, FR (HQ)
117 Avenue de Luminy
Rockville, US
2273 Research Blvd #350
Show all (2)

Innate Pharma Financials and Metrics

Innate Pharma Revenue

Innate Pharma's revenue was reported to be €85.81 m in FY, 2019
EUR

Revenue (FY, 2019)

85.8m

Net income (FY, 2019)

(20.8m)

EBIT (FY, 2019)

(27.1m)

Market capitalization (6-Aug-2020)

408.6m

Closing stock price (6-Aug-2020)

5.2

Cash (31-Dec-2019)

202.9m
Innate Pharma's current market capitalization is €408.6 m.
Annual
EURFY, 2017FY, 2018FY, 2019

Revenue

44.0m94.0m85.8m

Revenue growth, %

113%

General and administrative expense

17.0m18.1m

R&D expense

67.0m69.6m
Half Year
EURH1, 2018H1, 2019

Revenue

23.0m59.2m

General and administrative expense

5.6m9.3m

R&D expense

32.3m36.6m

Operating expense total

37.9m45.9m
Annual
EURFY, 2017FY, 2018FY, 2019

Cash

99.4m152.3m202.9m

Accounts Receivable

2.5m

Current Assets

137.5m319.6m237.6m

PP&E

10.7m10.2m11.7m
Quarterly
EURQ2, 2019

Cash

149.4m

Accounts Receivable

5.5m

Current Assets

216.7m

PP&E

11.4m
Annual
EURFY, 2017FY, 2018FY, 2019

Net Income

(48.4m)3.0m(20.8m)

Depreciation and Amortization

4.4m7.4m16.5m

Cash From Operating Activities

(48.1m)(32.5m)34.9m

Purchases of PP&E

(3.0m)(873.0k)
Quarterly
EURQ2, 2018Q2, 2019

Net Income

(15.1m)13.2m

Depreciation and Amortization

2.4m6.8m

Cash From Operating Activities

(33.9m)59.6m

Purchases of PP&E

(709.0k)(738.0k)
EURFY, 2017

EV/EBIT

-10.3 x

EV/CFO

-8.6 x

Revenue/Employee

234.2k

Debt/Equity

0.1 x

Financial Leverage

3 x
Show all financial metrics

Innate Pharma Operating Metrics

Q2, 2019

Phase I Trials Products

3

Phase II Trials Products

5

Pre-Clinical Phase Products

7
Show all operating metrics

Innate Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Innate Pharma France SAS
Innate Pharma Inc

Innate Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Innate Pharma Revenue Breakdown

Embed Graph

Innate Pharma revenue breakdown by business segment: 85.0% from Revenue from collaboration and licensing agreements and 15.0% from Government financing for research expenditures

Innate Pharma Online and Social Media Presence

Embed Graph

Innate Pharma News and Updates

Innate Pharma Announces Publication of EXPLORE COVID-19 Translational Study Findings in Nature

New research suggests targeting C5a-C5aR1 axis could limit severe inflammatory response New research suggests targeting C5a-C5aR1 axis could limit severe inflammatory response

Innate Pharma Announces the Appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer

Pierre Dodion, MD retires as Chief Medical Officer Pierre Dodion, MD retires as Chief Medical Officer

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 19, 2020 Without the Physical Presence of Its Shareholders

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 19, 2020 AM in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

Innate Pharma Reports Full Year 2019 Financial Results and Business Update

MARSEILLE, France, March 10, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending December 31, 2019. The consolidated financial statements are attached to…

Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial

MARSEILLE, France, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab (IPH4102) in patient…

Innate Pharma Provides Update on Lacutamab Tellomak Trial

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced an update regarding its TELLOMAK Phase II trial evaluating the efficacy and safety of lacutamab (IPH4102, a potentially first-in-class anti-KIR3DL2 antibody).  The Company will take the fo…
Show more

Innate Pharma Blogs

Number of shares and voting rights of Innate Pharma as at May 1, 2020

May 6, 2020 Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 …

First patient dosed in avdoralimab Phase II clinical trial in COVID-19 patients with severe pneumonia

April 28, 2020 Initial translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the fir…

Innate Pharma files its 2019 Universal Registration Document (Document d'enregistrement universel) and its 2019 annual report on Form 20-F

April 24, 2020 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2019 Universal Registration Document (Document d’enregistrement universel) for the year ended December 31, 201…

Innate Pharma reports Full Year 2019 financial results and business update

March 10, 2020 Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million*) Monalizumab to advance to a Phase III clinical trial in combination with cetu…

First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors

March 10, 2020 Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPH…

Full Year 2019 Results Conference Call

Body:  Innate Pharma to hold a conference call on 10th March 2020, 14:00 CET / 9:00 ET Link:  Access to webcast and dial in details Order:  1
Show more

Innate Pharma Frequently Asked Questions

  • When was Innate Pharma founded?

    Innate Pharma was founded in 1999.

  • Who are Innate Pharma key executives?

    Innate Pharma's key executives are Herve Brailly, Odile Laurent and Irina Staatz-Granzer.

  • How many employees does Innate Pharma have?

    Innate Pharma has 235 employees.

  • What is Innate Pharma revenue?

    Latest Innate Pharma annual revenue is €85.8 m.

  • What is Innate Pharma revenue per employee?

    Latest Innate Pharma revenue per employee is €365.2 k.

  • Who are Innate Pharma competitors?

    Competitors of Innate Pharma include Ablynx, Virttu Biologics and OncoDNA.

  • Where is Innate Pharma headquarters?

    Innate Pharma headquarters is located at 117 Avenue de Luminy, Marseille.

  • Where are Innate Pharma offices?

    Innate Pharma has offices in Marseille and Rockville.

  • How many offices does Innate Pharma have?

    Innate Pharma has 2 offices.